Hyatt Leads Hospitality Rally with Shorts Still Building

H rose 8.1% over the past week to $176.15, outpacing most of its closest peers but doing so against a backdrop where short interest has climbed nearly 20% over the past month, a combination that sharpens the setup ahead of Q3 earnings on October 29.

Among the major hotel brands, Hyatt's week sits comfortably above HGV at 2.9% and VAC at 4.4%, while HLT gained 9.0% and MAR added 6.9%. That puts Hyatt near the middle of the peer pack on momentum, not a laggard, but not leading the charge either. What separates Hyatt from those peers right now is the scale of short positioning. Short interest stands at 13.5% of the free float, built up from around 11.3% a month ago as shorts added meaningfully through early October. The monthly build of roughly 19.5% in short shares is the sharpest in the history shown here.

The borrow market does not reflect a crowded or panicked short. Cost to borrow sits near 0.63%, barely changed on the week and low by any measure. Availability is at 133% of short interest, meaning there are comfortably more shares available to lend than there are shorts outstanding. That is well above the tightest point of the past 52 weeks at 55%. Options positioning also leans constructive rather than defensive: the put/call ratio has eased to 0.21, below its 20-day average of 0.23, and is barely a fraction of a standard deviation from normal. None of these signals suggest the short book is under pressure or that protection buyers are especially active. The short position is large but not squeezed, and the cost of maintaining it remains negligible.

The Street is broadly positive, though with some trimming around the edges ahead of the print. Morgan Stanley raised its target to $211 earlier this month while maintaining Overweight, and Mizuho sits at $222. JP Morgan remained Overweight on Wednesday but cut its target by $2 to $207, a minor adjustment. Barclays and Wells Fargo both lifted targets this week. Against a current price of $176.15, the mean analyst target of $196.44 implies roughly 11.5% upside, a reasonable spread but not extreme. Factor scores reinforce a broadly favourable fundamental picture: EPS surprise ranks in the 82nd percentile and forward EPS growth in the 84th. The ORTEX short score, at 72, places short positioning in the top decile of the universe by pressure level, which sits in tension with what the borrow market is saying. Analyst recommendation divergence ranks in the 92nd percentile, reflecting a wide gap between the most bullish and most cautious targets on the Street.

Ownership is unusually concentrated. The Pritzker family and affiliated trusts control well over a third of shares outstanding, with Thomas Pritzker's trust filing a Schedule 13D amendment in January 2026 at 22.8% of the class. Three separate Pritzker-linked entities appear on the 13D register, which ORTEX confirms as activist-designated filings, though the practical read here is family control rather than external agitation. Baron Capital, which holds around 7.7% and added roughly 937,000 shares through June, is the most active institutional buyer in recent quarters. Wellington Management, by contrast, has trimmed from 11.5% to 6.9% since last year's filing. Insider activity over the past 90 days is net negative, at roughly 6,700 shares sold for just over $1.15 million in aggregate value. The CFO, Joan Bottarini, sold 1,826 shares on October 16 under a pre-arranged 10b5-1 plan, which limits the signal. A June sale by CEO Mark Hoplamazian totalling around $6.8 million, outside of any disclosed plan, is the more notable data point in the recent record.

The earnings history carries a clear asymmetry. The most recent print, in early August, produced a one-day move of just minus 0.7%. The prior quarter, reported at end of July, saw the stock drop 6.4% on the day and a further 3.8% over the following week. That divergence means the range of outcomes on October 29 is genuinely wide. The stock has re-rated sharply higher in the month leading into that print, up 13.6%, so how much of the improved RevPAR and development pipeline story the market has already priced will be the immediate question when numbers hit.